Tags : Boehringer Ingelheim

PharmaShots Weekly Snapshot (September 16– 20, 2019)

1.Boehringer Ingelheim Enters into an Agreement with Inflammasome Therapeutics to Co-Develop Therapies for Retinal Diseases Published: Sept 20, 2019 | Tags: Boehringer Ingelheim, Agreement, Inflammasome Therapeutics, Co-Develop, Therapies, Retinal Disease 2. Astellas and FibroGen’s Evrenzo (roxadustat) Receives MHLW’s Approval for Anemia Associated with Chronic Kidney Disease in Dialysis Patients Published: Sept 20, 2019 | Tags: Astellas, FibroGen, […]Read More

Boehringer Ingelheim Enters into an Agreement with Inflammasome Therapeutics to

Shots: Inflammasome to receive up to $160M up front, R&D milestone, commercialization milestone with royalties on sales of the developed product. The companies will co-develop up to three therapies for patients with retinal disease The focus of the agreement is to strengthen Boehringer’s retinal portfolio by combining with Inflammasome’s IVT drug delivery technology. The collaboration […]Read More

Boehringer Ingelheim Signs an Exclusive Worldwide License Agreement with Oncoheroes

Shots: Oncoheroes to get IP rights with an exclusive right to research, develop, sell and sublicense Boehringer’s Volasertib. Oncoheroes will further develop & commercialize volasertib for pediatric cancer indications The license agreement allows Boehringer to continue the clinical development of volasertib to benefit pediatric patients with cancer Volasertib is a Polo-like-kinase 1 inhibitor with strong […]Read More

PharmaShots Weekly Snapshot (September 02 – 06, 2019)

1.Roche’s Tecentriq + Chemotherapy Receives EC’s Approval as 1L Treatment for Extensive Stage Small Cell Lung Cancer Published: Sept 06, 2019 | Tags: Roche, Tecentriq, Chemotherapy, Receives, EC, Approval, Initial Treatment, Extensive Stage Small Cell Lung Cancer 2. OncoCyte to Acquire Razor Genomics for the Expansion of its Capabilities in Early-Stage Lung Cancer Published: Sept 05, 2019 […]Read More

Boehringer Ingelheim Enters into a Licensing Agreement with Lupin to

Shots: Lupin to receive $20M up front, ~$700M as clinical, regulatory & commercial milestones with royalties on sales of the product. Boehringer Ingelheim to get right to utilize Lupin’s LNP3794 in combination with its KRAS inhibitors for patients with gastrointestinal and lung cancers harboring KRAS mutations The focus of the agreement is to robust Boehringer’s […]Read More

PharmaShots Weekly Snapshot (August 12-16, 2019)

Profound Medical’s TULSA-PRO Receives the US FDA’s 510(k) Clearance for Ablation of Prostate Tissue Published: Aug 16, 2019 | Tags: 510(k), Ablation, Clearance, Profound Medical, Prostate Tissue, Receives, TULSA-PRO, The US FDA 2. Mallinckrodt Reports Positive Results of Terlipressin in P-III CONFIRM Study for Hepatorenal Syndrome Type 1 Published: Aug 16, 2019 | Tags: CONFIRM, Hepatorenal Syndrome […]Read More

Boehringer Ingelheim Signs a Multi-Year Agreement with University of Texas

Shots: The companies collaborated to establish a Virtual Research and Development Center, enabling data sharing and analysis and focusing on research of therapies for multiple types of cancers, including gastrointestinal and lung cancers The focus of the agreement is to combine novel therapies from Boehringer’s oncology pipeline with patient-driven drug-development capabilities of MD Anderson’s Therapeutics […]Read More